Saturday, July 11, 2026

Drug profile · INN

rezafungin

rezafungin (REZZAYO) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antiinfectives for systemic use (J02) J02AX08
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — rezafungin
Class
Antiinfectives for systemic use (J02)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

rezafungin (REZZAYO) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN rezafungin
Brand REZZAYO
Therapeutic class Antiinfectives for systemic use (J02)
ATC code J02AX08

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. CD101.IV.3.08 Phase 3 · Mundipharma · Invasive Fungal Diseases in Adults undergoing Allogeneic Blo
  2. REZZAYO 200 mg powder for concentrate for solution for infusion Phase 2 · Mundipharma · Chronic pulmonary aspergillosis (CPA)

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is rezafungin?

rezafungin (REZZAYO) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for rezafungin?

REZZAYO is a marketed brand name for rezafungin. Check FDA Drugs@FDA for the current US label holder and prescribing information.